The flowers are harvested by hand, dried under controlled conditions, and tested in the state-of-the-art laboratory for purity and active ingredient content. (Credit: Richard T on Unsplash)

Aurora Cannabis, the Canadian-based leading global medical cannabis company, announces today the launch of the company’s first German-cultivated medical cannabis product, under the brand IndiMed. Manufactured at Aurora’s leading EU-GMP facility in Leuna, Germany, the new brand offers a supply of high-quality, locally grown and sold, medical cannabis for the country’s expanding patient base.

“Aurora is proud to deliver to the rapidly growing German market our first domestically produced medical cannabis product – a significant step forward since Germany’s move to decriminalize cannabis earlier this year,” says Michael Simon, President, Aurora Europe (Interim). “As one of three facilities licensed to cultivate in Germany, we are uniquely positioned to offer domestic product from our EU-GMP facility in Leuna, Germany, which operates within Aurora’s global manufacturing network. It is through our expertise in cultivation and deep commitment to science and innovation that we introduce IndiMed to the German patients.”

The premium product launching from the IndiMed brand is Island Sweet Skunk, dried flower, sativa, 20% THC, <1 % CBD. Product is expected to be available on January 27. IndiMed is cultivated under GACP and EU-GMP guidelines to ensure pharmaceutical-grade quality. The flowers are harvested by hand, dried under controlled conditions, and tested in the state-of-the-art laboratory for purity and active ingredient content.

Aurora leads the global medical cannabis industry with unmatched expertise, driving innovation and progress. Its steadfast commitment to growth in the dynamic German market cements its position as the industry’s unrivaled leader.

Aurora’s expertise in navigating complex European regulatory frameworks and manufacturing high-quality medical cannabis positions the company as the preferred leader to drive progress in the German market with confidence. By continually setting new global benchmarks, Aurora reinforces its status as the world’s largest medical cannabis company operating in nationally legal markets.